ArticlePloS one2014
Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Esophageal Squamous Cell Carcinoma and Gastric Cardia Adenocarcinoma Shared Susceptibility Locus in C20orf54: Evidence from Published Studies.Scientific reports · 2015Pooled it
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.British journal of cancer · 2015Pooled it
- New Approaches to Screening for Barrett Esophagus.Gastroenterology & hepatology · 2025Article
- Cost-effective identification of Barrett's esophagus in the community: A first step towards screening.Journal of gastroenterology and hepatology · 2024Article
- Long-term risk factors for developing Barrett's oesophagus in patients with gastro-oesophageal reflux disease: a longitudinal cohort study.BMJ open gastroenterology · 2024Article
- Development and validation of a multivariable risk factor questionnaire to detect oesophageal cancer in 2-week wait patients.Clinics and research in hepatology and gastroenterology · 2023Article
- Risk Prediction of Barrett's Esophagus in a Taiwanese Health Examination Center Based on Regression Models.International journal of environmental research and public health · 2021Article
- Risk Prediction Models for Barrett's Esophagus Discriminate Well and Are Generalizable in an External Validation Study.Digestive diseases and sciences · 2020Article
- Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach.The Lancet. Digital health · 2020Article
- Use of the Electronic Health Record to Target Patients for Non-endoscopic Barrett's Esophagus Screening.Digestive diseases and sciences · 2019Article
- Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.Gastroenterology · 2018Article
- Validation of a risk prediction model for Barrett's esophagus in an Australian population.Clinical and experimental gastroenterology · 2018Article
- Conference report: improving outcomes for gastrointestinal cancer in the UK.Frontline gastroenterology · 2018Review
- Risk stratifying the screening of Barrett's esophagus: An Asian perspective.JGH open : an open access journal of gastroenterology and hepatology · 2017Article
- Evolving management of metaplasia and dysplasia in Barrett's epithelium.World journal of gastroenterology · 2016Review
- Precision prevention of oesophageal adenocarcinoma.Nature reviews. Gastroenterology & hepatology · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundBarrett's esophagus (BE) occurs as consequence of reflux and is a risk factor for esophageal adenocarcinoma. The current "gold-standard" for diagnosing BE is endoscopy which remains prohibitively expensive and impractical as a population screening tool. We aimed to develop a pre-screening tool to aid decision making for diagnostic referrals. METHODOLOGY/PRINCIPAL
findingsA prospective (training) cohort of 1603 patients attending for endoscopy was used for identification of risk factors to develop a risk prediction model. Factors associated with BE in the univariate analysis were selected to develop prediction models that were validated in an independent, external cohort of 477 non-BE patients referred for endoscopy with symptoms of reflux or dyspepsia. Two prediction models were developed separately for columnar lined epithelium (CLE) of any length and using a stricter definition of intestinal metaplasia (IM) with segments ≥ 2 cm with areas under the ROC curves (AUC) of 0.72 (95%CI: 0.67-0.77) and 0.81 (95%CI: 0.76-0.86), respectively. The two prediction models included demographics (age, sex), symptoms (heartburn, acid reflux, chest pain, abdominal pain) and medication for "stomach" symptoms. These two models were validated in the independent cohort with AUCs of 0.61 (95%CI: 0.54-0.68) and 0.64 (95%CI: 0.52-0.77) for CLE and IM ≥ 2 cm, respectively.
conclusionsWe have identified and validated two prediction models for CLE and IM ≥ 2 cm. Both models have fair prediction accuracies and can select out around 20% of individuals unlikely to benefit from investigation for Barrett's esophagus. Such prediction models have the potential to generate useful cost-savings for BE screening among the symptomatic population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.